Cervical carcinosarcoma

Summary

Cervical carcinosarcoma (MONDO:0002877) is a disease and 1 clinical trial. Top therapeutic interventions include bevacizumab. A subtype of uterine carcinosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical carcinosarcoma
Mondo ID	MONDO:0002877
Orphanet	213787
DOID	DOID:4112
NCIT	C36097
SNOMED CT	764951002
UMLS	C1332917
MedGen	232338
GARD	0020491
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: carcinosarcoma of the cervix uteri · cervical carcinosarcoma · cervical malignant mixed mesodermal (Mullerian) tumor · cervical malignant mixed mesodermal (Mullerian) tumour · cervical malignant mixed mesodermal (Müllerian) tumor · cervical malignant mixed mesodermal (Müllerian) tumour · cervical malignant mixed mesodermal mullerian tumour · cervical malignant mixed Mullerian tumour · cervical malignant Mullerian mixed tumor · cervical malignant Mullerian mixed tumour · cervical malignant Müllerian mixed tumor · cervical malignant Müllerian mixed tumour · malignant Mullerian mixed tumor of the cervix uteri · malignant Mullerian mixed tumour of the cervix uteri · malignant Müllerian mixed tumor of the cervix uteri · malignant Müllerian mixed tumour of the cervix uteri · uterine cervix carcinosarcoma

Disease family

This is a subtype of uterine carcinosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinosarcoma › cervical carcinosarcoma

Related subtypes (1): carcinosarcoma of the corpus uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1